DRUGinvestigationalsmall molecule
Sulforaphane
Mechanism
NRF2 activator (natural product)
Related claims (14)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| gene expression | Sulforaphane (SUFP) at 4 mg/kg upregulates Nrf2, HO-1, and SIRT1 expression in methylmercury-induced ALS-like pathology. | 69% | 41649614 |
| pathway membership | Sulforaphane suppresses stress-related signaling pathways including p75NTR, PI3K/Akt, and MAPKs in methylmercury-induced ALS-like pathology. | 65% | 41649614 |
| safety | Sulforaphane exhibits reduced systemic toxicity compared to dimethyl fumarate while being slightly less efficacious in methylmercury-induced ALS-like pathology. | 53% | 41649614 |
| protein interaction | Sulforaphane interacts with Nrf2-Keap1 targets to exert antioxidant and anti-inflammatory mechanisms. | 53% | 41649614 |
| drug efficacy | Sulforaphane is identified as a multifaceted therapeutic candidate for ALS with a well-tolerated safety profile. | 53% | 41649614 |
| neuroprotection | Sulforaphane treatment attenuates demyelination and preserves neuronal architecture in cortical, hippocampal, and cerebellar regions in methylmercury-induced ALS-like pathology. | 53% | 41649614 |
| motor function | Sulforaphane treatment improves grip strength in methylmercury-induced ALS-like pathology. | 47% | 41649614 |
| motor function | Sulforaphane treatment improves locomotor performance in methylmercury-induced ALS-like pathology. | 47% | 41649614 |
| gene expression | Sulforaphane suppresses apoptotic markers Bax and caspase-3 in methylmercury-induced ALS-like pathology. | 45% | 41649614 |
| drug efficacy | Sulforaphane exhibits superior neuroprotection compared to omaveloxolone with a favorable safety profile in methylmercury-induced ALS-like pathology. | 45% | 41649614 |
| biomarker | Sulforaphane stabilizes neurofilament and myelin-associated proteins in methylmercury-induced ALS-like pathology. | 45% | 41649614 |
| gene expression | Sulforaphane suppresses pro-inflammatory cytokines IL-1β and TNF-α in methylmercury-induced ALS-like pathology. | 45% | 41649614 |
| safety | Sulforaphane normalizes hepatic enzymes in methylmercury-induced ALS-like pathology. | 39% | 41649614 |
| neuroprotection | Sulforaphane improves skeletal muscle integrity in methylmercury-induced ALS-like pathology. | 39% | 41649614 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.